Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Not all c-kit mutations can be corrected by imatinib.

Laboratory investigation; a journal of technical methods and pathology - 1 Apr 2007

Lasota Jerzy

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Benzamides
Share to Imatinib Mesylate
Share to Mastocytosis, Systemic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphorylation

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Source

Identifiers

PMID: 17486696

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Not all c-kit mutations can be corrected by imatinib.PMID 17486696Read ↗

c-Kit Receptors as a Therapeutic Target in Cancer: Current InsightsSemantic proximity Read ↗

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.Semantic proximity Read ↗

[The significance of C-KIT gene mutations in the diagnosis and prognosis of malignant tumors].Semantic proximity Read ↗

Chronic mast cell leukaemia with exon 9 KIT mutation A502_Y503dup: a rare imatinib responsive variant.Semantic proximity Read ↗

Kit as a human oncogenic tyrosine kinase.Semantic proximity Read ↗

Imatinib: the promise of a "magic bullet" for cancer fulfilled.Semantic proximity Read ↗

Imatinib resistance in chronic myeloid leukemia due to a rare mutation.Semantic proximity Read ↗

A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitorsSemantic proximity Read ↗

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.Semantic proximity Read ↗

[Mutations of c-kit receptor tyrosine kinase in hematologic disease].Semantic proximity Read ↗

[Tyrosine kinases in etiopathogenesis and therapy of malignant diseases--C-kit activating mutations].Semantic proximity Read ↗

The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.